A Phase 3 interventional study of Brinzolamide 1% ophthalmic suspension and Azopt 1% Ophthalmic Suspension in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Padagis LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-06.
Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brinzolamide in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. brinzolamide · Glaucoma, Open-Angle.
Among the 28 studies testing brinzolamide in Glaucoma, Open-Angle, this one is the 6th largest by enrollment, is the only one that started in 2019, is one of 10 in phase 3, and was the 28th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →None of the 28 studies testing brinzolamide in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →
brinzolamide: first FDA approval 1998 (AZOPT), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 495 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 209 across the 28 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 6 most frequent:
Padagis LLC is the lead sponsor of 37 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Padagis LLC has 2 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brinzolamide in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the safety and efficacy of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test product
Drug: Brinzolamide 1% ophthalmic suspension
Azopt ophthalmic suspension
Drug: Azopt 1% Ophthalmic Suspension
Test product
Reference product
Mean Change in Intra-ocular Pressure
mean change in intra-ocular pressure of both eyes at four time points : at approximately 8:00 a.m. (hour 0; before the morning drop) and approximately 10:00 a.m. (hour 2) on Day 14 (Week 2) and Day 42 (Week 6) visits.
Time frame: 6 weeks
| Milestone | Perrigo Active | Reference Active |
|---|---|---|
| Started | 249 | 246 |
| Completed | 247 | 237 |
| Not completed | 2 | 9 |
mean change in intra-ocular pressure of both eyes at four time points : at approximately 8:00 a.m. (hour 0; before the morning drop) and approximately 10:00 a.m. (hour 2) on Day 14 (Week 2) and Day 42 (Week 6) visits.
| mmHG | Perrigo Active | Reference Active |
|---|---|---|
| 8AM Day 14 | -4.25 ± 2.713 | -3.80 ± 2.719 |
| 10AM Day 14 | -4.22 ± 2.722 | -4.00 ± 2.756 |
| 8AM Day 42 | -4.43 ± 2.967 | -4.20 ± 2.591 |
| 10AM Day 42 | -4.05 ± 2.961 | -4.06 ± 2.842 |
Collected over Day 1 to Day 46. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Perrigo Active | 0/249 (0%) | 0/249 (0%) | 32/249 (12.9%) |
| Reference Active | 0/246 (0%) | 1/246 (0.4%) | 36/246 (14.6%) |
| Event | Perrigo Active | Reference Active |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | — | 1/246 |
| Event | Perrigo Active | Reference Active |
|---|---|---|
| DysgeusiaNervous system disorders | 23/249 | 21/246 |
| vision blurredEye disorders | 9/249 | 15/246 |
| Age, Categorical(Participants) | Perrigo Active | Reference Active | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 98 | 96 | 194 |
| >=65 years | 151 | 150 | 301 |
| Age, Continuous(years) | Perrigo Active | Reference Active | Total |
|---|---|---|---|
| Mean | 65.8 ± 9.85 | 65.6 ± 11.12 | 65.7 ± 10.49 |
| Sex: Female, Male(Participants) | Perrigo Active | Reference Active | Total |
|---|---|---|---|
| Female | 145 | 132 | 277 |
| Male | 104 | 114 | 218 |
| Ethnicity (NIH/OMB)(Participants) | Perrigo Active | Reference Active | Total |
|---|---|---|---|
| Hispanic or Latino | 25 | 31 | 56 |
| Not Hispanic or Latino | 223 | 215 | 438 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Perrigo Active | Reference Active | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 5 | 10 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 81 | 84 | 165 |
| White | 161 | 155 | 316 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Iris Color(Participants) | Perrigo Active | Reference Active | Total |
|---|---|---|---|
| Right eye — Dark | 158 | 163 | 321 |
| Right eye — Light | 91 | 83 | 174 |
| Left eye — Dark | 158 | 162 | 320 |
| Left eye — Light | 91 | 84 | 175 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Feb 2020, 8 months.
Results were first posted in Mar 2023, 3 years after primary completion.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 8 months is below that.
Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brinzolamide